Real-time ultrasound elastography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.
To evaluate the application of ultrasound elastography (ES) in monitoring treatment response to brentuximab vedotin (Seattle Genetics, Seattle, WA, USA). Patients were selected when suffering from relapsed and refractory Hodgkin Lymphoma (HL). Our research investigated if the interim of ultrasound ES is a predictive value for treatment outcome in patients treated with brentuximab vedotin. 30 patients with refractory HL were enrolled. After treatment with brentuximab vedotin, 14 patients were classified as responders and 16 were classified as non-responders. At baseline, there was no difference between the groups both in the strain ratio (z = 1.1, p = 0.3) and in the volume (z = -0.3, p = 0.8). While after treatment there was a difference between the groups both in the strain ratio (z = -2.09, p < 0.05) and in the volume (z = 4.1, p < 0.001). Real-time elastosonography could be a reliable tool for the assessment of refractory Hodgkin lymphoma response to brentuximab vedotin treatment and help to identify patient with improved clinical outcome early during treatment. Results indicate that changes in ultrasound elastosonography parameters are correlated with the clinical and pathologic response of patients. These findings could pave the way for establishing protocols for the clinical applications of ultrasound elastography techniques in therapy response monitoring.